AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03592238 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Trier Social Stress Test for Children
Description: Participants will be asked to imagine that they are in a new class with 20 other students, and that their teacher has asked them to stand in front of the class and introduce themselves. The mental arithmetic task will entail asking children to serially subtract the number 5 from a larger number as quickly as possible.
Study NCT03592238 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Seated Rest
Description: Children will be asked to sit quietly or read a book of their choosing.
Study NCT04249102 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guardian Connect, Medtronic
Description: Guardian Connect is real-time continuous glucose sensor systems which provide glucose information updated every 5 minutes
Study NCT04249102 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Abbott Diabetes Care
Description: Abbott Diabetes Care is a Flash Glucose Monitoring system that provides up to 8 hours of retrospective continuous glucose monitoring data to users when the monitor is waved in proximity with the sensor.
Study NCT01778530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC105
Description: Intravenous infusion.
Study NCT02563054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: Participants will receive 5-FU, 800 milligrams per meter-squared (mg/m\^2) per day via IV infusion during Days 1 to 5 of each 3-week cycle, for a total of 6 cycles in combination with cisplatin or upto disease progression.
Study NCT02563054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Participants will receive oral capecitabine, 1000 mg/m\^2 twice daily on Days 1 to 14 of each 3-week cycle, for a total of 6 cycles in combination with cisplatin or upto disease progression.
Study NCT02563054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Participants will receive cisplastin, 80 mg/m\^2 via IV infusion on Day 1 of each 3-week cycle, for a total of 6 cycles or upto disease progression in combination with either capecitabine or 5-FU.
Study NCT01954082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: myo-Inositol 5% Injection
Description: Abbott Nutrition Division, Abbott Laboratories is supplying myo-Inositol 5% Injection to the clinical centers for the duration of the trial.~Inositol: myo-Inositol 5% Injection is an isotonic, preservative-free, sterile 5% solution of myo-inositol in water containing 0.5 gm sodium chloride per liter (8.55mM), pH 6.5-7.5. It is administered via IV infusion using syringe pump over 15-30 minutes twice per day at 12-hour intervals at a dose of 80 mg inositol/kg/day (40 mg inositol/kg/dose), which is equivalent to 1.6 mL/kg/day (0.80 mL/kg/dose).
Study NCT01954082 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: % glucose(dextrose)
Study NCT02563054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Participants will receive cisplastin, 80 mg/m\^2 via IV infusion on Day 1 of each 3-week cycle, for a total of 6 cycles or upto disease progression in combination with either capecitabine or 5-FU.
Study NCT02355639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05 % ointment
Study NCT02355639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone dipropionate 0.064 % ointment
Study NCT02355639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Petrolatum ointment
Study NCT03499249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl cysteine
Description: Intravenous NAC therapy (6.25 mg/kg/hour of 10 mg/ml solution, or 0.625 ml/kg/hour, to give 150 mg/kg/day), starting within 24 hours of completion of KP and lasting for a total of 7 days
Study NCT01188005 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: n-CPAP
Description: administration of continuous positive airway pressure through a nasal device
Study NCT01188005 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxygen supplementation
Description: Oxygen supplementation (3L) through nasal spectacles
Study NCT01188005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin A, Vitamin C, Vitamin E, Allopurinol, N-Acetylcysteine
Description: Vitamin A 50,000 IU, Vitamin C 1000 mg , Vitamin E 200 mg, Allopurinol 600 mg, N-Acetylcysteine 2 g. Duration is set for 60 days
Study NCT04088734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABO-102
Description: Single dose of ABO-102 (scAAV9.U1a.hSGSH) administered by intravenous injection through a peripheral limb vein at a dose of 3 X 10\^13 vg/kg
Study NCT00379366 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: External ionizing radiations
Description: 14 Gy in one time
Study NCT00583765 — intervention group
Intervention type: DRUG
Intervention: Regional citrate anticoagulation
Description: Continuous venovenous hemodiafiltration with regional anticoagulation using dilute trisodium citrate. This requires the use of a continuous renal replacement therapy (CRRT) machine in venovenous hemodiafiltration mode. Anticoagulation and buffer are provided by the use of a dilute solution of trisodium citrate in the replacement fluid which is infused in a predilution mode. Standard bicarbonate containing dialysate is used.
Study NCT02323425 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischemic postconditioning
Description: Remote ischemic postconditioning（RIPC）treatment was performed by the inflating a cuff around bilateral arms to 180 mmHg with 5 cycles of 3 min inflation and 5 min relax alternation automatically.
Study NCT04277598 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo gel for topical administration.
Study NCT02972619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured Multicomponent Intervention (MCI)
Description: Multicomponent Intervention (MCI) includes 1) algorithm-driven antihypertensive treatment for all hypertensive individuals using fixed-dose combination (FDC) and lipid lowering for high risk hypertensive individuals, 2) motivational conversation for high-risk hypertensive individuals and 3) telephone based follow-ups of all hypertensive individuals by a team of physician supervised nurse, and 4) discounts on FDC antihypertensive medications
Study NCT02445261 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: mobile phone
Description: Each woman was subjected to 15 minutes CTG trace recording before using mobile phone and repeated while the phone is in the dialing mode for 10 minutes. Umbilical artery (UA) Doppler ultrasound was done after the initial CTG trace and was repeated 5 minutes after hanging up the mobile phone.
Study NCT04455100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1459/Itraconazole
Description: SHR1459 will be administered on Day 1 and Day 7. Itraconazole will be administered on Day 4 to Day 8
Study NCT00815880 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-Pulse™ (Implantable Counterpulsation Therapy)
Description: Implantation and activation of counterpulsation therapy for the full duration of the study period. The device may be turned off briefly for personal hygiene, etc.
Study NCT00287235 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MARS
Study NCT00287235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Medical Therapy
Study NCT00287235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Therapy
Study NCT01842230 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg
Description: * Telmisartan 80mg, S-amlodipine 5mg: 1 tablet, oral, once daily, 1day~* Atorvastatin 40mg: 1 tablet, oral, once daily, 2days~* over the period I \& II(cross-over)
Study NCT01842230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg
Description: * Telmisartan 80mg, S-amlodipine 5mg: 1 tablet, oral, once daily, 1day~* Atorvastatin 40mg: 1 tablet, oral, once daily, 2days~* over the period I \& II(cross-over)
Study NCT01842230 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan 80mg and S-amlodipine 5mg
Description: * Telmisartan 80mg, S-amlodipine 5mg: 1 tablet, oral, once daily, 1day~* over the period I \& II(cross-over)
Study NCT01842230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan 80mg and S-amlodipine 5mg
Description: * Telmisartan 80mg, S-amlodipine 5mg: 1 tablet, oral, once daily, 1day~* over the period I \& II(cross-over)
Study NCT02300831 — intervention group
Intervention type: OTHER
Intervention: Data Collection
Description: Non interventional prospective data collection
Study NCT01778855 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IV t-PA and normothermia
Study NCT01778855 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IV-tPA and hypothermia
Study NCT04618523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine
Description: Artemisinin-based combination treatment
Study NCT04618523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Description: Artemisinin-based combination treatment
Study NCT03602378 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: salivary cortisol
Description: 5 samples of saliva (first sample before around 22:00 and other samples the next morning, after awakening (00, 15, 30 and 60 minutes).
Study NCT03602378 — intervention group
Intervention type: DEVICE
Intervention: Holter Medilog AR12 Plus
Description: Holter Medilog AR12 Plus - electrocardiogram during 5 minutes for measuring HRV
Study NCT03602378 — intervention group
Intervention type: DEVICE
Intervention: Polar V800
Description: Polar V800 with sensor - during 5 minutes for measuring HRV
Study NCT03602378 — intervention group
Intervention type: DEVICE
Intervention: AGE reader
Description: for measuring Advanced Glycation End products (AGEs)
Study NCT02069015 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient education
Description: Patient education on hypertension delivered through a touchscreen kiosk.
Study NCT01119859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: The maximum dose was 800 mg for patients weighing more than 100 kg. Tocilizumab was infused into an arm vein over a 1-hour period.
Study NCT01119859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Study NCT01119859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to tocilizumab
Study NCT01119859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to adalimumab
Study NCT01585974 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: All dosage, frequency and duration for drugs will be under the decision of the treating physician
Study NCT01131169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan, melphalan and fludarabine
Description: Patients will be cytoreduced with IV busulfan, melphalan and fludarabine. Busulfan will be administered at a dose of 0.8mg/Kg q6hrs for 10 doses on days -9, -8, -7. Doses for busulfan should be adjusted according to pharmacokinetic studies. Melphalan will be administered at a dose of 70 mg/m2/day for 2 days on days -7, -6. Fludarabine will be administered at a dose of 25 mg/m2/day for 5 days on days -6, -5, -4, -3, -2. Patients will also receive rabbit anti-thymocyte globulin (ATG) to prevent immune mediated graft rejection. The ATG will be administered at a dose of 2.5 mg/Kg/day IV on days -3 and -2. Doses for busulfan, melphalan and ATG should be adjusted if patient is > 125% ideal body weight and should be calculated on adjusted ideal body weight.
Study NCT00722137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab 375 mg/m^2
Description: Intravenous rituximab 375 mg/m\^2 on Day 1 of a 21-day (3 week) cycle for 6 cycles.
Study NCT00722137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab 375 mg/m^2
Description: Intravenous rituximab 375 mg/m\^2 on Day 1 of a 21-day (3 week) cycle for 6 cycles.
Study NCT00722137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide 750 mg/m^2
Description: Intravenous cyclophosphamide 750 mg/m\^2 on Day 1 of a 21-day (3 week) cycle for 6 cycles
Study NCT00722137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 750 mg/m^2
Description: Intravenous cyclophosphamide 750 mg/m\^2 on Day 1 of a 21-day (3 week) cycle for 6 cycles
Study NCT00722137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin 50 mg/m^2
Description: Intravenous doxorubicin 50 mg/m\^2 on Day 1 of a 21-day (3 week) cycle for 6 cycles
Study NCT00722137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin 50 mg/m^2
Description: Intravenous doxorubicin 50 mg/m\^2 on Day 1 of a 21-day (3 week) cycle for 6 cycles
Study NCT00722137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VELCADE 1.3 mg/m^2
Description: Intravenous VELCADE 1.3 mg/m\^2 on Days 1,4,8, and 11of a 21-day (3 week) cycle for 6 cycles
Study NCT00722137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone 100 mg/m^2
Description: Oral prednisone 100 mg/m\^2 on Day 1 to Day 5 of a 21-day (3 week) cycle for 6 cycles
Study NCT02966574 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: whole body MRI
Description: The examination will be conducted in the pretreatment assessment of breast cancers with a high metastasis risk and in the monitoring of metastatic breast cancers. The examination is performed without intravenous injection of contrast medium, from the top of the skull to mid-thigh using diffusion weighted sequences in the axial plane, T1-weighted sequences in the coronal plane, STIR T2 weighted sequences in the coronal plane and T1-weighted sequences in the sagittal plane on the spine. Total examination duration is one hour. The interpretation of the results is made by two independent reporters with a complementary expertise, according to a systematic lecture grid.
Study NCT00722137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 100 mg/m^2
Description: Oral prednisone 100 mg/m\^2 on Day 1 to Day 5 of a 21-day (3 week) cycle for 6 cycles
Study NCT00722137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine 1.4 mg/m^2
Description: Intravenous vincristine 1.4 mg/m\^2 on Day 1of a 21-day (3 week) cycle for 6 cycles. Maximum of 2 mg. Participants could receive 8 cycles if a response was initially documented at the Cycle 6 assessment.
Study NCT03033589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marcaine 0.25 % Injectable Solution
Description: For the adductor canal block, 20 mL of 0.25% marcaine will be injected with the use of ultrasound guidance into the adductor canal by the attending anesthesiologist on the case in the pre-op holding area.
Study NCT03033589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marcaine 0.25 % Injectable Solution
Description: For the femoral nerve block, 30 mL of 0.25% marcaine will be injected with the use of ultrasound guidance around the femoral nerve sheath by the attending anesthesiologist on the case in the pre-op holding area.
Study NCT01455441 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training and liraglutide
Study NCT01455441 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Training and placebo
Study NCT02574923 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow Mononuclear Cells
Description: Transplantation of Autologous Bone Marrow Mononuclear Cells
Study NCT05209113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: A self-management module was applied to the study group. This module includes informing the patient verbally and in writing about MS disease, the importance of drug compliance, and monitoring of disease symptoms.
Study NCT00819182 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Paced respiration
Description: Breathing exercise
Study NCT00819182 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham comparator: fast shallow breathing
Description: sham breathing exercise
Study NCT00782613 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4,4-dimethyl-benziso-2H-selenazine
Description: ALT-2074 in a 0.5% cream formulation
Study NCT00782613 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in a cream formulation
Study NCT06350019 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Penile revascularızation
Description: The importance of resistive index in the preoperative evaluation of vascular-induced erectile dysfunction, predicting the success of penile revascularization surgery, and postoperative patient management was investigated.
Study NCT02408614 — intervention group
Intervention type: OTHER
Intervention: Slow-paced walking
Description: Subjects will complete 47 minutes of walking on a treadmill at a slow-pace.
Study NCT00572247 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychiatric Rehabilitation Approach to Weight Loss
Description: The use of psychiatric rehabilitation as a way to lose weight
Study NCT04278365 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive affect training
Description: Behavioral training involving position emotion enhancement
Study NCT03538522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-831(Traneurocin) 10 mg QD
Description: Oral administration of 10 mg capsule of NA-831 QD for 24 weeks
Study NCT03538522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NA-831 (Traneurocin) 20 mg QD
Description: Oral administration of 20 mg capsule of NA-831 QD for 24 weeks
Study NCT02408614 — intervention group
Intervention type: OTHER
Intervention: Moderate-paced walking
Description: Subjects will complete 47 minutes of walking on a treadmill at a moderate pace.
Study NCT02408614 — intervention group
Intervention type: OTHER
Intervention: Interval Training
Description: Subjects will complete 40 minutes of walking on the treadmill alternating between a moderate and a fast pace.
Study NCT02408614 — intervention group
Intervention type: DEVICE
Intervention: Treadmill
Study NCT03538522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NA-831 (Traneurocin) 40 mg QD
Description: Oral administration of 40 mg capsule of NA-831 QD or for 24 weeks
Study NCT03538522 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule QD
Description: Oral administration of oral placebo capsule QD or 24 weeks
Study NCT01010230 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMHF mechanical stimulation active device
Description: Participants will be randomly assigned to stand on a low magnitude, high frequency mechanical stimulation device (vibrating) platform for 10 minutes twice daily for one year. The study hypothesizes participants in the intervention arm intervention will demonstrate improved total bone mineral content for height, spinal and tibial bone mineral density and tibial bone strength when compared to those who are randomized to the placebo intervention.
Study NCT01010230 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: LMHF mechanical stimulation placebo device
Description: Participants will be randomly assigned to stand on a low magnitude, high frequency mechanical stimulation device (vibrating) platform for 10 minutes twice daily for one year. The study hypothesizes participants in the intervention arm intervention will demonstrate improved total bone mineral content for height, spinal and tibial bone mineral density and tibial bone strength when compared to those who are randomized to the placebo intervention.
Study NCT00896701 — intervention group
Intervention type: OTHER
Intervention: flow cytometry
Study NCT00896701 — intervention group
Intervention type: OTHER
Intervention: immunologic technique
Study NCT04251468 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: GEPII
Description: Saliva probes (K+Sa) will be measured using genetically encoded potassium ion indicators (GEPIIs)
Study NCT04251468 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ion-selective electrodes
Description: Plasma potassium levels (K+Pl) will be measured using standard ion-selective electrodes.
Study NCT02552836 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy
Description: A 12-week intervention that focuses on resolving interpersonal stressors that are linked to the onset, maintenance or exacerbation of depressive symptoms
Study NCT02552836 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Psychotherapy
Description: A 12-week intervention that focuses on non-specific factors that contribute to therapy outcome
Study NCT03841786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phosphorus-supplemented study diet
Description: Participants will be instructed to consume a normal diet and will take a total of 1,000 mg of supplemental phosphorus per day in the form of neutral sodium phosphorus (K-Phos neutral®) for 1 week.
Study NCT03841786 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Diet
Description: Participants will be asked to consume a normal diet supplemented with sodium and potassium chloride tablets commensurate with the extra sodium and potassium content consumed during the study diet period for 1 week
Study NCT03786783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT03786783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Description: Given IV